Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 4/20 | 0.66 |
| ▸ | MAOB | P27338 | 8/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.59 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607851 | 0.92 | NPC1 (0.67) | GAPDHMAOBCA1CA2NPC1 | |
| SCHEMBL21091107 | 0.87 | NPC1 (0.67) | GAPDHMAOBNPC1RAB9ARXFP1 | |
| SCHEMBL803489 | 0.85 | GAPDH (0.68) | GAPDHMAOBCA1CA2NPC1 | |
| SCHEMBL7124497 | 0.85 | MAOB (0.86) | GAPDHMAOBCA1CA2NPC1 | |
| SCHEMBL12691924 | 0.84 | GAPDH (0.57) | GAPDHMAOBCA1CA2NPC1 | |
| SCHEMBL9607852 | 0.84 | RAB9A (0.63) | GAPDHMAOBNPC1RAB9ARXFP1 | |
| SCHEMBL803185 | 0.83 | THRB (0.59) | GAPDHMAOBCA1CA2NPC1 | |
| SCHEMBL21587890 | 0.82 | NPC1 (0.61) | GAPDHMAOBNPC1RAB9ARXFP1 | |
| SCHEMBL20355398 | 0.81 | NPC1 (0.74) | GAPDHMAOBNPC1RAB9ARXFP1 | |
| SCHEMBL20052531 | 0.81 | NPC1 (0.74) | GAPDHMAOBNPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660130-B1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GMBH (DE) | 2021-08-04 | — | — | EP | disclosed |
| US-11015121-B2 | Liquid crystal displays and liquid crystalline media with homeotropic alignment | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2021-05-25 | — | — | US | disclosed |
| EP-3660130-A1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | Merck Patent GmbH (DE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190256771-A1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2019-08-22 | — | — | US | disclosed |
| US-10273409-B2 | Liquid crystal displays and liquid crystalline media with homeotropic alignment | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2019-04-30 | — | — | US | disclosed |
| EP-2652087-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-30 | — | — | EP | disclosed |
| US-20180022997-A1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022997-A1 | LIQUID CRYSTAL DISPLAYS AND LIQUID CRYSTALLINE MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9868904-B2 | Liquid crystal displays and liquid crystalline media with homeotropic alignment | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9868904-B2 | Liquid crystal displays and liquid crystalline media with homeotropic alignment | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-01-16 | — | — | US | disclosed |
| WO-2011110287-A1 | POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL MEDIA AND LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011107213-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107218-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011098224-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011029510-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
| US-20100272925-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100272925-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2243812-A2 | Liquid crystal display | Merck Patent GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010089092-A1 | LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272925-A1 | LIQUID-CRYSTAL DISPLAY | KLK3, BPHL, LPXN | GAPDH 1510/4885MAOB 1671/4885CA1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.